American Century Companies Inc. Raises Position in Alder BioPharmaceuticals, Inc. (ALDR)

American Century Companies Inc. increased its position in Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 29.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 91,052 shares of the biopharmaceutical company’s stock after buying an additional 20,566 shares during the quarter. American Century Companies Inc. owned about 0.18% of Alder BioPharmaceuticals worth $1,043,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ALDR. Legal & General Group Plc raised its position in Alder BioPharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 400 shares during the period. Teachers Advisors LLC raised its position in Alder BioPharmaceuticals by 1.5% in the fourth quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock valued at $1,598,000 after purchasing an additional 1,171 shares during the period. Baird Financial Group Inc. raised its position in Alder BioPharmaceuticals by 7.9% in the first quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 1,349 shares during the period. Swiss National Bank raised its position in Alder BioPharmaceuticals by 2.6% in the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after purchasing an additional 1,700 shares during the period. Finally, American International Group Inc. raised its position in Alder BioPharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 28,849 shares of the biopharmaceutical company’s stock valued at $600,000 after purchasing an additional 1,910 shares during the period. 76.16% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/09/17/american-century-companies-inc-raises-position-in-alder-biopharmaceuticals-inc-aldr.html.

In other news, Director Stephen M. Dow bought 25,000 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was purchased at an average price of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.60% of the stock is owned by insiders.

Several research firms have commented on ALDR. ValuEngine raised Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. Leerink Swann reissued an “outperform” rating and issued a $32.00 price objective on shares of Alder BioPharmaceuticals in a research report on Monday, June 12th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Alder BioPharmaceuticals in a research report on Friday, June 9th. Wells Fargo & Company reissued an “outperform” rating and issued a $51.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $47.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $30.62.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) opened at 10.20 on Friday. The stock’s 50 day moving average price is $9.66 and its 200 day moving average price is $16.05. Alder BioPharmaceuticals, Inc. has a 52 week low of $8.60 and a 52 week high of $35.62. The firm’s market capitalization is $690.67 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.67) by $0.19. The firm had revenue of $0.68 million for the quarter. Alder BioPharmaceuticals’s revenue was up 518.2% on a year-over-year basis. During the same period last year, the company posted ($0.79) earnings per share. On average, analysts predict that Alder BioPharmaceuticals, Inc. will post ($5.74) EPS for the current fiscal year.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply